Hybridomas are hybrid cell lines formed by fusion of a B cell (e.g., of mouse-origin) with an immortal B myeloma cell. Each hybridoma is able to constitutively produce one specific target monoclonal antibody (mAb). The mAbs that are produced are chemically identical, which qualifies them for various in vivo applications, such as diagnostics, therapeutics, targeted biologics, etc.